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Chapter 3
Models of Open and Closed State Blockers
So far we have studied a one-dimensional model of calcium-induced calcium
release. The analysis started with a stochastic differential equation modeling release
from internal storage to the dyad. We found that this model could be analyzed
using Monte Carlo simulations or a system of deterministic partial differential
equations giving the probability density functions of the open and the closed
states. Furthermore, we found analytical solutions of the stationary solutions of the
probability density system.
The aim of the present chapter is to introduce mathematical models of a drug
and then show how the parameters defining the drug can be computed so that it
works as well as possible. For simplicity, we will focus on closed to open mutations
(CO-mutations; see page 16), but it will become clear how to handle open to closed
mutations (OC-mutations) in later chapters.
Let us start by recalling that the Markov model governing the states of the






When a CO-mutation is present, we introduce the mutation severity index  and






Obviously,  D 1 represents the wild type case and the size of  > 1 gives the
strength of the mutation. By recalling what the Markov model means, we see that
the mutation increases the probability of going from the closed to the open state and
thus the open state probability will increase.
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In this chapter, we will study theoretical open and closed state blockers. We recall




















respectively. The reasoning behind this way of modeling the effect of a drug was
discussed on page 18 above; see in particular Fig. 1.9. Basically, we assume that
the drug introduces a new conformational state of the channel protein that can be
attained via the open state (for open state blockers) or via the closed state (for closed
state blockers). The blocked states are always assumed to be non-conducting.
The mathematical problem of finding a suitable theoretical drug is now to find
the parameters kbc and kcb for the closed state blockers and kbo and kob for the open
state blockers such that the effect of the mutation is reduced as much as possible.
We will see that this problem is much easier using the probability density approach
than using Monte Carlo simulations.
To compute optimal drugs for the CO-mutation, we will first consider the
equilibrium states of the reactions. For closed state blockers, we can use the
equilibrium considerations to reduce the number of free parameters from two to
one. In principle, this can also be done for open state blockers, but some averaging
is needed in the process and optimality is not obtained. For the closed state blocker,
we can use the steady state system derived above to completely characterize both
parameters of the drug to obtain optimality and computations will show that the
resulting drug is theoretically extremely good and asymptotically perfect in the
sense that it completely reverses the effect of the mutation. We are also able to
derive a good open state blocker, but the method is less satisfactory and the results
are not as good as for the closed state blocker.
3.1 Markov Models of Closed State Blockers
for CO-Mutations
We start the derivation of theoretical drugs by considering closed state blockers. The
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where the reaction rates of the drug given by kcb and kbc must be determined so that
the mutated cell behaves as similarly to the wild type cell as possible. We regard
these parameters as free and we seek to compute them to obtain optimal efficiency
of the theoretical drug. Allow us also to briefly repeat that this is basically our
definition of a theoretical drug as discussed on page 18.
3.1.1 Equilibrium Probabilities for Wild Type






and let o denote the probability of being in the open state and c the probability of
being in the closed state. Suppose the channel just flickers between open and closed
and nothing else happens. Then the equilibrium probabilities are characterized by
kcoc D koco: (3.6)
This means that the channel keeps on flickering in equilibrium and the probabilities












3.1.2 Equilibrium Probabilities for the Mutant Case
In the CO-mutation case, we assume that the rate from C to O is increased and we
define
kco; D kco; (3.7)
58 3 Models of Open and Closed State Blockers
where  > 1 and  D 1 denotes wild type. The equilibrium open probability of the







which clearly increases with increasing values of .
3.1.3 Equilibrium Probabilities for Mutants with a Closed
State Drug
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Now, we want to choose the drug characterization ıc such that o;ıc  o and this





ıc    1:
So we obtain the characterization
kcb D .  1/kbc: (3.9)
This means that, for the closed state blocker, we reduced the number of parameters
characterizing the blocker from two to one. We will use the probability density
approach to determine the remaining degree of freedom.
3.2 Probability Density Functions in the Presence of a Closed
State Blocker
















.acb/ D kcbc  kbcb;
where
ao D vr.c1  x/ C vd.c0  x/;
ac D vd.c0  x/:
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From (3.9), the parameters of the drug are related by
kcb D .  1/ kbcI (3.10)















.acb/ D .  1/ kbcc  kbcb:
In the stationary case, we obtain the system
@
@x
.aoo/ D kcoc  koco; (3.11)
@
@x
.acc/ D koco  .kco C .  1/ kbc/ c C kbcb; (3.12)
@
@x
.acb/ D .  1/ kbcc  kbcb: (3.13)
In this system, the mutation severity is given by  and the drug is characterized by
a single parameter given by kbc. For a given value of  our aim is now to compute
the value of kbc such that the probability density function of the open state given by
this system is as similar as possible to the probability density function of the open
state in the case of  D 1, that is, the wild type solution when no drug is applied.
3.2.1 Numerical Simulations with the Theoretical Closed State
Blocker
We consider a mutation characterized by  D 3 and we apply closed state blockers
(see reaction scheme (3.5)) with parameters satisfying the relation (3.10). In Fig. 3.1,
we show the results of these simulations using the Monte Carlo approach: The lower
panel of the figure is the same as the upper panel, except that we focus on concen-
trations ranging from 80 to 91 M . We observe significant differences between
the wild type solution and the solution representing the mutation. Furthermore, we
observe that the drug works quite well. Similar results are given in Fig. 3.2, where
the computations are based on the probability density approach: Here the lower
panel focuses on very high concentrations ranging from 89 to 91 M. We also see
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Fig. 3.1 Monte Carlo simulations using the theoretical closed state blocker given by the reaction
scheme (3.5), where the reaction rates are related by (3.10) and the mutation severity index is given
by  D 3. The lower panel focuses on higher levels of concentrations
that the closed state drug improves as the value of kbc increases. In fact, the result
seems to indicate that the drug is asymptotically perfect in the sense that the solution
converges toward the wild type solution when kbc ! 1. Model parameters for these
simulations are given in Table 3.1.
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Fig. 3.2 Numerical solutions of the steady state probability density functions defined by the
system (3.11)–(3.13), where the reaction rates are related by (3.10) and the mutation severity index
is given by  D 3. The lower panel focuses on higher levels of concentrations. Note that the
concentration axis of this figure is different from that of the lower panel of Fig. 3.1
Table 3.1 Parameter values





kco.x/ 0:1x ms1 M1
koc 1 ms1
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3.3 Asymptotic Optimality for Closed State Blockers
in the Stationary Case
In the simulations above, we observed that the closed state blocker worked well and
that the drug became more effective as the value of kbc increased. Our aim is now
to indicate that, when kbc ! 1, the drug will completely repair the mutation. It
is worth mentioning that the possibility of making a drug with kbc D 1 is quite
unlikely, but the asymptotic result is still of theoretical interest.
Consider the steady state system
@
@x
.aoo/ D kcoc  koco; (3.14)
@
@x
.acc/ D koco  .kco C .  1/ kbc/ c C kbcb; (3.15)
@
@x
.acb/ D .  1/ kbcc  kbcb: (3.16)
By adding all the equations, we obtain
@
@x
.aoo C ac .c C b// D 0: (3.17)
From the boundary conditions, we obtain




.aoo C acb/ ; (3.19)
where we recall that ac < 0 for x 2 .c0; cC/. Now, the system (3.14)–(3.16) can be
rewritten in the form
@
@x











.acb/ D  .  1/ ao
ac
o  b: (3.21)
We are interested in solutions of this system as kbc becomes very large and we
therefore note that, in the limit as kbc ! 1; the second equation yields
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and therefore the first equation becomes
@
@x














































(see (2.36)). By comparing (3.26) and (3.27), we see that when the drug is chosen
to be of the form
kcb D .  1/ kbc
and when we let kbc ! 1; the drug completely repairs the probability density
functions of the mutated cell.
3.4 Markov Models for Open State Blockers
Next, we want to consider models of open state blockers. The reaction scheme of an










The equilibrium probabilities are now characterized by
kcoc D koco;
kbob D koboI
















We now define the open state blocker characterization
ıo D kob
kbo















we want to choose the drug such that o;ıo  o and we therefore require
koc
kco








where we recall that the mutation severity index  > 1: Since  D 1 is the wild
type case, we note that in that case ıo D 0 is the optimal drug, which makes sense;
there is no need to drug the wild type. However, for mutant cells, we have  > 1
and the characterization (3.28) of ıo depends on the dyad calcium concentration, x:
We will therefore use direct optimization to find suitable open state blockers.
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3.4.1 Probability Density Functions in the Presence
of an Open State Blocker















.acb/ D kobo  kbob; (3.31)
where we recall that
ao D vr.c1  x/ C vd.c0  x/;
ac D vd.c0  x/:
In the stationary case, we obtain the system
@
@x
.aoo/ D kcoc  .koc C kob/o C kbob; (3.32)
@
@x
.acc/ D koco  kcoc; (3.33)
@
@x
.acb/ D kobo  kbob: (3.34)
We let both kob and kbo be free parameters and use the Fminsearch function
in Matlab to optimize these parameters by minimizing the discrete l2 difference1
between the wild type and mutant o. The resulting parameters are kob D 0:28 ms1,
and kbo D 1:63 ms1 and the associated numerical results are given in Fig. 3.3,
marked as opt.
3.5 Open Blocker Versus Closed Blocker
In Fig. 3.4, we compare the results of the best open state blocker (referred to as
opt in Fig. 3.3) and closed state blocker, using kbc D 1;000 ms1 (see Fig. 3.2).
We clearly see that the closed state blocker is better; in fact, at this resolution of
1The discrete l2 difference between two vectors is given by ku  vk2 D .
P
i.ui  vi/2/1=2.
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Fig. 3.3 Graphs of the numerical solutions using open state blockers. The open state blockers are
based on optimization using the Fminsearch function in Matlab. In the simulation marked with opt,
both parameters kob and kbo are used in the minimization










Fig. 3.4 Comparison of the best open state blocker and closed state blocker using kbc D 1;000
ms1 (see Table 3.2 for all the parameters of the two drugs). It is hard to distinguish between the
wild type solution and the solution of the mutant case where the closed state blocker is applied
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Table 3.2 Parameter values





the graphs, it is hard to distinguish the wild type solution from the solution of the
mutant case where the closed state blocker is applied.
3.6 CO-Mutations Does Not Change the Mean Open Time
To understand why the closed state blocker is much better than the open state blocker



































the mean open time is changed and reads
o D 1
koc C kob :
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With a closed state blocker used to repair a CO-mutation, the mean open time is kept
constant, as it should, but it is changed using an open state blocker. Consequently, it
is hard to see how to derive an efficient open state blocker for a CO-mutation.
3.7 Notes
1. In this chapter we focused on CO-mutations (see page 16) and, for such
mutations, closed state blockers are best suited from a theoretical perspective.
We will see later that OC-mutations are more easily repaired using open state
blockers.
2. The argument of asymptotic optimality given on page 63 is not a rigorous
proof. To prove it mathematically, we have to take the boundary layer into
consideration. Our derivation assumes smooth solutions but that assumption does
not hold at the boundary.
3. In this section, we used probability density formulations for systems with more
than two states. The general case of many states is presented in Appendix C of
Huertas and Smith [35].
4. The mean open time will be introduced and analyzed in Chap. 13. In the present
chapter we just used very basic properties.
5. We mentioned above that we used the function Fminsearch in Matlab to solve a
minimization problem; see page 66. The Fminsearch function uses the Melder-
Nead [58] algorithm studied by Lagarias et al. [46]. The method is very powerful
and will be used routinely in these notes.
6. It is an underlying assumption for Markov models that the states of the model
correspond to the conformational states of the channel protein. This should not
be interpreted literally; rather, it has proved to be a useful modeling technique.
A thorough discussion on the modeling of ion channels using Markov models
and the models relation to the states of the protein is provided by Rudy and Silva
[75].
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